PO2RDF: representation of real-world data for precision oncology using resource description framework

被引:1
作者
Zhao, Yiqing [1 ]
Dimou, Anastasios [2 ]
Shen, Feichen [1 ]
Zong, Nansu [1 ]
Davila, Jaime, I [4 ]
Liu, Hongfang [1 ]
Wang, Chen [3 ]
机构
[1] Mayo Clin, Div Digital Hlth Sci, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN USA
[3] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN 55905 USA
[4] St Olaf Coll, Dept Math Stat & Comp Sci, Northfield, MN 55057 USA
关键词
Resource description framework; Precision oncology; Electronic health records; Real-world evidence; INDIVIDUALIZED MEDICINE; EGFR; SYSTEM; CANCER; KNOWLEDGEBASE; CHEMOTHERAPY; VARIANTS; THERAPY; IMPACT;
D O I
10.1186/s12920-022-01314-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Next-generation sequencing provides comprehensive information about individuals' genetic makeup and is commonplace in precision oncology practice. Due to the heterogeneity of individual patient's disease conditions and treatment journeys, not all targeted therapies were initiated despite actionable mutations. To better understand and support the clinical decision-making process in precision oncology, there is a need to examine real-world associations between patients' genetic information and treatment choices. Methods To fill the gap of insufficient use of real-world data (RWD) in electronic health records (EHRs), we generated a single Resource Description Framework (RDF) resource, called PO2RDF (precision oncology to RDF), by integrating information regarding genes, variants, diseases, and drugs from genetic reports and EHRs. Results There are a total 2,309,014 triples contained in the PO2RDF. Among them, 32,815 triples are related to Gene, 34,695 triples are related to Variant, 8,787 triples are related to Disease, 26,154 triples are related to Drug. We performed two use case analyses to demonstrate the usability of the PO2RDF: (1) we examined real-world associations between EGFR mutations and targeted therapies to confirm existing knowledge and detect off-label use. (2) We examined differences in prognosis for lung cancer patients with/without TP53 mutations. Conclusions In conclusion, our work proposed to use RDF to organize and distribute clinical RWD that is otherwise inaccessible externally. Our work serves as a pilot study that will lead to new clinical applications and could ultimately stimulate progress in the field of precision oncology.
引用
收藏
页数:12
相关论文
共 49 条
[1]   AACR Project GENIE: Powering Precision Medicine through an International Consortium [J].
Andre, Fabrice ;
Arnedos, Monica ;
Baras, Alexander S. ;
Baselga, Jose ;
Bedard, Philippe L. ;
Berger, Michael F. ;
Bierkens, Mariska ;
Calvo, Fabien ;
Cerami, Ethan ;
Chakravarty, Debyani ;
Dang, Kristen K. ;
Davidson, Nancy E. ;
Del Vecchio, Fitz Catherine ;
Dogan, Semih ;
DuBois, Raymond N. ;
Ducar, Matthew D. ;
Futreal, P. Andrew ;
Gao Jianjiong ;
Garcia, Francisco ;
Gardos, Stu ;
Gocke, Christopher D. ;
Gross, Benjamin E. ;
Guinney, Justin ;
Heins, Zachary J. ;
Hintzen, Stephanie ;
Horlings, Hugo ;
Hudecek, Jan ;
Hyman, David M. ;
Kamel-Reid, Suzanne ;
Kandoth, Cyriac ;
Kinyua, Walter ;
Kumari, Priti ;
Kundra, Ritika ;
Ladanyi, Marc ;
Lefebvre, Celine ;
LeNoue-Newton, Michele L. ;
Lepisto, Eva M. ;
Levy, Mia A. ;
Lindeman, Neal, I ;
Lindsay, James ;
Liu, David ;
Lu Zhibin ;
MacConaill, Laura E. ;
Ian, Maurer ;
Maxwell, David S. ;
Meijer, Gerrit A. ;
Meric-Bernstam, Funda ;
Micheel, Christine M. ;
Miller, Clinton ;
Mills, Gordon .
CANCER DISCOVERY, 2017, 7 (08) :818-831
[2]  
Aronson AR., 2006, DHHS, V1, P26
[3]   PharmGKB: A worldwide resource for pharmacogenomic information [J].
Barbarino, Julia M. ;
Whirl-Carrillo, Michelle ;
Altman, Russ B. ;
Klein, Teri E. .
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 2018, 10 (04)
[4]   Erlotinib in cancer treatment [J].
Bareschino, M. A. ;
Schettino, C. ;
Troiani, T. ;
Martinelli, E. ;
Morgillo, F. ;
Ciardiello, F. .
ANNALS OF ONCOLOGY, 2007, 18 :35-41
[5]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[6]  
Bizer C, 2004, P 3 INT SEM WEB C PR
[7]   The Unified Medical Language System (UMLS): integrating biomedical terminology [J].
Bodenreider, O .
NUCLEIC ACIDS RESEARCH, 2004, 32 :D267-D270
[8]   EGFR in melanoma: clinical significance and potential therapeutic target [J].
Boone, Barbara ;
Jacobs, Koen ;
Ferdinande, Liesbeth ;
Taildeman, Jasmien ;
Lambert, Jo ;
Peeters, Marc ;
Bracke, Marc ;
Pauwels, Patrick ;
Brochez, Lieve .
JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (06) :492-502
[9]  
Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011
[10]   Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer [J].
Chan, David Lok Hang ;
Segelov, Eva ;
Wong, Rachel S. H. ;
Smith, Annabel ;
Herbertson, Rebecca A. ;
Li, Bob T. ;
Tebbutt, Niall ;
Price, Timothy ;
Pavlakis, Nick .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (06)